Investigational drug · Phase 2
Radspherin
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Peritoneal Carcinomatosis, Ovarian Cancer, Peritoneal Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: May 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "Radspherin"
First trial start
2020
May 27, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Radspherin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Peritoneal Carcinomatosis
- Ovarian Cancer
- Peritoneal Carcinoma
- Colorectal Carcinoma
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Radspherin" as an intervention, largest first.
- A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking SurgeryPivotal-lookingRecruiting
Oncoinvent Solutions ASIndustry
NCT06504147 · 114 participants (planned) · Start Jun 15, 2024 · Primary completion Feb 29, 2028
Drug: Radspherin · For: Peritoneal Carcinomatosis; Ovarian Cancer
Sites: Tampa, Florida; Leuven, Belgium; Roma, Italy · 10 sites in all
Oncoinvent Solutions ASIndustry
NCT03732781 · 47 participants · Start May 27, 2020 · Primary completion May 14, 2025
Drug: Radspherin · For: Peritoneal Carcinoma; Colorectal Carcinoma
Sites: Oslo, Norway; Uppsala, Sweden
Oncoinvent Solutions ASIndustry
NCT03732768 · 21 participants · Start Jun 8, 2020 · Primary completion Sep 30, 2025
Drug: Radspherin · For: Peritoneal Carcinomatosis; Ovarian Cancer
Sites: Leuven, Belgium; Oslo, Norway; Madrid, Spain · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- [Innovative practices in the diagnosis and treatment of peritoneal surface malignancies: insights from the 15th congress of the Peritoneal Surface Oncology Group International (PSOGI)].
Koh E · Zhonghua Wei Chang Wai Ke Za Zhi 2026
- Experiences and Hopes Among Patients with Colorectal Carcinoma and Peritoneal Metastases Who Are Participating in an Early-Phase Clinical Trial.
Fauske L, Bruland ØS, Holtermann A, et al. · Cancers (Basel) 2026
- First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer.
Wang Y, Van Nieuwenhuysen E, Revheim ME, et al. · Gynecol Oncol 2026
- Eighteen-Months Safety and Efficacy Following Intraperitoneal Treatment With 224Radium-Labeled Microparticles After CRS-HIPEC in Patients With Peritoneal Metastasis From Colorectal Cancer.
Larsen SG, Graf W, Larsen RH, et al. · J Surg Oncol 2024
- First experience with 224Radium-labeled microparticles (Radspherin®) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study).
Larsen SG, Graf W, Mariathasan AB, et al. · Front Med (Lausanne) 2023
- Effect of Intraperitoneal 224Radium-Labelled Microparticles on Compartmentalized Inflammation After Cytoreductive Surgery and Hypertherm Intraperitoneal Chemotherapy.
Thorgersen EB, Asvall J, Schjalm C, et al. · Technol Cancer Res Treat 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.